Welcome to our dedicated page for Allogene Therapeutics news (Ticker: ALLO), a resource for investors and traders seeking the latest updates and insights on Allogene Therapeutics stock.
Allogene Therapeutics, Inc. (Nasdaq: ALLO) is a clinical-stage biotechnology company developing allogeneic CAR T (AlloCAR T) therapies for cancer and autoimmune disease. The ALLO news feed on Stock Titan aggregates company announcements, clinical updates, and regulatory disclosures so readers can follow how its AlloCAR T pipeline progresses through development.
News about Allogene frequently highlights key milestones in its major programs. For oncology, updates include progress in the pivotal Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma, including trial design changes, site activations, and planned interim analyses focused on minimal residual disease (MRD) conversion. For autoimmune disease, releases cover the Phase 1 RESOLUTION trial of ALLO-329, a dual CD19/CD70 AlloCAR T candidate that incorporates the company’s Dagger® technology and is being studied across multiple rheumatologic indications.
Investors and observers can also find news on ALLO-316 in renal cell carcinoma through the TRAVERSE trial, including early clinical response data and discussions with regulators about potential pivotal development. Additional items include quarterly financial results, cash runway commentary, participation in investor and medical conferences, and 8-K summaries of material events such as changes in lymphodepletion strategy or intellectual property developments involving licensed TALEN-based gene-editing technology.
By following ALLO news, readers can track clinical catalysts, safety and biomarker findings, regulatory interactions, and corporate updates that may influence perceptions of Allogene’s AlloCAR T platform and its potential applications in hematologic malignancies, solid tumors, and autoimmune diseases.
Allogene Therapeutics (Nasdaq: ALLO) expanded its pivotal Phase 2 ALPHA3 trial to South Korea and Australia, growing the study from 60+ to over 80 global sites.
Screening and enrollment are expected to begin in Q2 2026; the study aims for ~220 patients by end-2027 with interim EFS analysis in mid-2027.
Allogene Therapeutics (Nasdaq: ALLO) is presenting multiple scientific posters and sessions at AACR Annual Meeting, April 17-22, 2026 in San Diego. Key highlights include a poster on BCMA/CD70 dual CAR T for high-risk multiple myeloma (poster 1535) and symposium talks on off-the-shelf allogeneic CAR T.
The company emphasizes its Dagger® gene-edited platform, extension into autoimmune disease applications, and goals of speed, safety, simplicity, scalability and improved survival with allogeneic CAR T.
Allogene Therapeutics (Nasdaq: ALLO) closed an underwritten public offering on April 16, 2026, selling 87,500,000 shares at $2.00 per share and 12,700,000 additional shares from the underwriters' option, raising $200.4 million in aggregate gross proceeds before fees.
Allogene expects to use net proceeds for general corporate purposes, which may include clinical trial expenses, research and development, general and administrative costs, and capital expenditures. The offering was completed off a shelf registration declared effective April 25, 2024, and a final prospectus supplement was filed with the SEC.
Allogene Therapeutics (Nasdaq: ALLO) announced pre-clinical data for ALLO-329, a dual-targeted CD19/CD70 allogeneic CAR T, published in Nature Communications.
Preclinical results show the CD70 CAR may protect against immune rejection, enabling robust CAR T expansion and persistence and suppressing autoantibody production in SLE models. A Phase 1 RESOLUTION dose-escalation trial is enrolling; initial human translational data from the first 20M-cell dose cohort are expected in June 2026.
Allogene Therapeutics (Nasdaq: ALLO) priced an underwritten public offering of 87,500,000 common shares at $2.00 per share, expected to raise gross proceeds of $175 million. The offering is expected to close on or about April 16, 2026.
Allogene granted underwriters a 30-day option to purchase up to 13,125,000 additional shares. Net proceeds may be used for general corporate purposes, including clinical trial and R&D expenses.
Allogene (Nasdaq: ALLO) intends to sell $175 million of common stock in an underwritten public offering announced April 13, 2026, with a 30-day underwriter option to purchase up to $26.25 million additional shares. The offering is subject to market conditions and may not be completed.
Net proceeds are expected to fund general corporate purposes, including clinical trial and R&D expenses, general and administrative costs, and capital expenditures. Goldman Sachs, Jefferies and TD Cowen are joint book-running managers; TPG Capital BD is co-manager. Shares will be offered from a shelf registration declared effective April 25, 2024.
Natera highlighted Allogene Therapeutics' interim futility analysis from the ALPHA3 trial (ALLO) on April 13, 2026. The analysis reported 58.3% MRD clearance with cema-cel and a median 97.7% ctDNA decrease at Day 45 versus a 26.6% median increase in observation.
The trial uses Natera's CLARITY MRD assay to randomize MRD-positive LBCL patients to cema-cel or observation; results are interim and final clinical outcomes remain pending.
Allogene (Nasdaq: ALLO) reported interim futility results from the randomized Phase 2 ALPHA3 trial in first-line consolidation large B-cell lymphoma showing 58.3% MRD negativity with cemacabtagene ansegedleucel (cema-cel) versus 16.7% on observation (a 41.6% absolute difference) at Day 45.
Plasma ctDNA fell a median 97.7% in the cema-cel arm vs a 26.6% median increase in observation. No CRS, ICANS, GvHD, or treatment-related serious adverse events were reported; 10 of 12 cema-cel patients were managed outpatient. Enrollment of ~220 patients expected to complete by end-2027; interim EFS analysis anticipated mid-2027, primary EFS mid-2028.
Allogene (Nasdaq: ALLO) will present interim futility analysis data from its pivotal, randomized Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel (cema-cel) in first-line consolidation large B-cell lymphoma (LBCL) on Monday, April 13, 2026.
The company will host a live conference call and webcast at 5:30 a.m. PT / 8:30 a.m. ET; the webcast will be available under the Investors / News and Events section at the company website.
Allogene (Nasdaq: ALLO) reported Q4 and full-year 2025 results and provided program updates. Key points: $258.3 million in cash and investments as of Dec 31, 2025; cash runway extended into Q1 2028. Pivotal ALPHA3 interim futility analysis planned for April 2026; RESOLUTION data expected June 2026.
2025 net loss was $190.9 million; guidance for 2026 operating cash expense is ~$150 million and GAAP operating expenses ~$210 million.